Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 321-334 , September 2008

Three-Dimensional Imaging-Based Radiobiological Dosimetry

References 

  1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  2. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053S–7063S
  3. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639–1647
  4. Chiavassa S, Aubineau L, Bitar A, et al. Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code. Phys Med Biol. 2006;51:601–616
  5. Flux GD, Webb S, Ott RJ, et al. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging. J Nucl Med. 1997;38:1059–1066
  6. Furhang EE, Chui CS, Kolbert KS, et al. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys. 1997;24:1163–1172
  7. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301–308
  8. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80(suppl):2591–2610
  9. Tagesson M, Ljungberg M, Strand SE. A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol. 1996;35:367–372
  10. Sgouros G, Kolbert KS, Zaidi H. The three-dimensional internal dosimetry software package, 3D-ID (Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine). Philadelphia: Institute of Physics; 2002;
  11. Guy MJ, Flux GD, Papavasileiou P, et al. RMDP: A dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003;18:61–69
  12. Johnson TK, McClure D, McCourt S. MABDOSE (I: Characterization of a general purpose dose estimation code). Med Phys. 1999;26:1389–1395
  13. Johnson TK, McClure D, McCourt S. MABDOSE (II: Validation of a general purpose dose estimation code). Med Phys. 1999;26:1396–1403
  14. Liu A, Williams LE, Wong JY, et al. Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry. Nucl Med Biol. 1998;25:423–433
  15. Clairand I, Ricard M, Gouriou J, et al. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med. 1999;40:1517–1523
  16. Yoriyaz H, Stabin MG, dos SA. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med. 2001;42:662–669
  17. Yoriyaz H, dos SA, Stabin MG, et al. Absorbed fractions in a voxel-based phantom calculated with the MCNP-4B code. Med Phys. 2000;27:1555–1562
  18. Descalle MA, Hartmann Siantar CL, Dauffy L, et al. Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy. Cancer Biother Radiopharm. 2003;18:71–79
  19. Bolch WE, Bouchet LG, Robertson JS, et al. MIRD pamphlet No. 17: The dosimetry of nonuniform activity distributions–radionuclide S values at the voxel level (Medical Internal Radiation Dose Committee). J Nucl Med. 1999;40:11S–36S
  20. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. New York: The Society of Nuclear Medicine; 1978;
  21. Snyder WS, Ford MR, Warner GG, Watson SB. “S” Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs (MIRD Pamphlet No. 11). New York: Society of Nuclear Medicine; 1975;
  22. Stabin MG MIRDOSE. Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–546
  23. Stabin MG, Sparks RB. OLINDA: PC-based software for biokinetic analysis and internal dose calculations in nuclear medicine. J Nucl Med. 2003;44:103P
  24. Stabin MG, Sparks RB, Crowe EB, et al. Olinda/Exm 1.0 and Radar. Eur J Nucl Med Mol Imaging. 2004;31:S471–S471
  25. Aubineau-Laniece I, de Carlan L, Clairand I, et al. Current developments at IRSN on computational tools dedicated to assessing doses for both internal and external exposure. Radiat Protection Dosimetry. 2005;115:522–529
  26. Chiavassa S, Bardies M, Guiraud-Vitaux F, et al. OEDIPE: A personalized dosimetric tool associating voxel-based models with MCNPX. Cancer Biother Radiopharmaceuticals. 2005;20:325–332
  27. Ferrer L, Chouin N, Bitar A, et al. Implementing dosimetry in GATE: Dose-point kernel validation with GEANT4 4.8.1. Cancer Biother Radiopharmaceuticals. 2007;22:125–129
  28. Visvikis D, Bardies M, Chiavassa S, et al. Use of the GATE Monte Carlo package for dosimetry applications. Nucl Instr Methods Phys Res Sect A. 2006;569:335–340
  29. Descalle MA, Siantar CH, Walling R. Validation of an internal source model in the PEREGRINE system for targeted radionuclide therapy. Med Phys. 2002;29:1234–1235
  30. Siantar CLH, Walling RS, Daly TP, et al. Description and dosimetric verification of the PEREGRINE Monte Carlo dose calculation system for photon beams incident on a water phantom. Med Phys. 2001;28:1322–1337
  31. Zheng Z, Cardarelli G, Shearer D, et al. Peregrine as a verification tool of Corvus treatment planning system. Med Phys. 2002;29:1231–1232
  32. Ljungberg M, Sjogreen K, Liu X, et al. A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: Evaluation for (131)I using monte carlo simulation. J Nucl Med. 2002;43:1101–1109
  33. Ljungberg M, Frey E, Sjogreen K, et al. 3D absorbed dose calculations based on SPECT: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm. 2003;18:99–107
  34. Sgouros G, Barest G, Thekkumthala J, et al. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31:1884–1891
  35. Mohan R, Barest G, Brewster LJ, et al. A comprehensive three-dimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys. 1988;15:481–495
  36. Sgouros G, Chiu S, Pentlow KS, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med. 1993;34:1595–1601
  37. Baechler S, Hobbs RF, Prideaux AR, et al. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35:1123–1134
  38. Sgouros G, Squeri S, Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med. 2003;44:260–268
  39. Kolbert KS, Sgouros G, Scott AM, et al. Dose-volume histogram representation of patient dose distribution in 3-dimensional internal dosimetry. J Nucl Med. 1994;35:P123–P124
  40. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–1372
  41. Kolbert KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with I-131 by use of I-124 PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48:143–149
  42. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008–1016
  43. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557–1562
  44. Ljungberg M, Strand SE, King MA. Monte Carlo Calculations in Nuclear Medicine. Bristol: Institute of Physics Publishing; 1998;
  45. Zaidi H, Sgouros G. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Philadelphia: Institute of Physics Publishing; 2003;
  46. Jaszczak RJ, Coleman RE, Whitehead FR. Physical factors affecting quantitative measurements using camera-based single photon-emission computed-tomography (SPECT). IEEE Trans Nucl Sci. 1981;28:69–80
  47. Jaszczak RJ, Greer KL, Floyd CE, et al. Improved SPECT quantification using compensation for scattered photons. J Nucl Med. 1984;25:893–900
  48. Jaszczak RJ, Whitehead FR, Lim CB, et al. Lesion detectability of rotating camera-based single photon-emission computed-tomography (SPECT). J Nucl Med. 1981;22:39–39
  49. Leichner PK, Koral KF, Jaszczak RJ, et al. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys. 1993;20:569–577
  50. Almquist H, Palmer J, Ljungberg M, et al. Quantitative SPECT by attenuation correction of the projection set using transmission data: Evaluation of a method. Eur J Nucl Med. 1990;16:587–594
  51. Dewaraja YK, Ljungberg M, Majumdar A, et al. A parallel Monte Carlo code for planar and SPECT imaging: Implementation, verification and applications in I-131 SPECT. Comput Methods Programs Biomed. 2002;67:115–124
  52. Ljungberg M, King MA, Hademenos GJ, et al. Comparison of four scatter correction methods using Monte Carlo simulated source distributions. J Nucl Med. 1994;35:143–151
  53. Ljungberg M, Strand SE. Attenuation correction in SPECT based on transmission studies and Monte Carlo simulations of build-up functions. J Nucl Med. 1990;31:493–500
  54. Ljungberg M, Strand SE. Scatter and attenuation correction in SPECT using density maps and Monte Carlo simulated scatter functions. J Nucl Med. 1990;31:1560–1567
  55. Ljungberg M, Strand SE. Attenuation and scatter correction in SPECT for sources in a nonhomogeneous object: A Monte Carlo study. J Nucl Med. 1991;32:1278–1284
  56. Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to I-131. J Nucl Med. 2002;43:972–982
  57. Sjorgreen K, Ljungberg M, Strand SE. Parameters influencing volume and activity quantitation in SPECT. Acta Oncol. 1996;35:323–330
  58. Beekman FJ, Kamphuis C, Frey EC. Scatter compensation methods in 3D iterative SPECT reconstruction: A simulation study. Phys Med Biol. 1997;42:1619–1632
  59. de Jong HW, Wang WT, Frey EC, et al. Efficient simulation of SPECT down-scatter including photon interactions with crystal and lead. Med Phys. 2002;29:550–560
  60. Du Y, Frey EC, Wang WT, et al. Combination of MCNP and SimSET for Monte Carlo simulation of SPECT with medium- and high-energy photons. IEEE Trans Nucl Sci. 2002;49:668–674
  61. Frey EC, Tsui BMW, Gullberg GT. Improved estimation of the detector response function for converging beam collimators. Phys Med Biol. 1998;43:941–950
  62. He B, Du Y, Song X, et al. A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT. Phys Med Biol. 2005;50:4169–4185
  63. He B, Frey EC. Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using In-111 agents. Phys Med Biol. 2006;51:3967–3981
  64. He B, Wahl R, Du Y, et al. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning: Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008;27:521–530
  65. Kadrmas DJ, Frey EC, Tsui BM. Simultaneous technetium-99m/thallium-201 SPECT imaging with model-based compensation for cross-contaminating effects. Phys Med Biol. 1999;44:1843–1860
  66. Segars WP, Tsui BM, Lalush DS, et al. Development and application of the new dynamic Nurbs-based cardiac-torso (NCAT) phantom. J Nucl Med. 2001;42:7p;(abstr)
  67. Lewellen T, Harrison R, Vannoy S. The SimSET program, in Monte Carlo calculations in nuclear medicine: applications in diagnostic imaging. In:  Ljungberg M,  Strand S-E,  King M editor. Monte Carlo Calculations in Nuclear Medicine (Applications in Diagnostic Imaging). Bristol, UK: Institute of Physics; 1998;p. 77–92
  68. Du Y, Tsui BMW, Frey EC. Model-based compensation for quantitative I-123 brain SPECT imaging. Phys Med Biol. 2006;51:1269–1282
  69. Frey EC, He B, Sgouros G, et al. Comparison of planar, quantitative SPECT, and combined planar-quantitative SPECT organ residence time estimation methods for targeted radionuclide therapy dosimetry. J Nucl Med. 2004;45:46P (abstr)
  70. He B, Frey EC, Sgouros G, et al. Comparison of conventional planar, quantitative planar, quantitative SPECT and combined planar-SPECT organ residence time estimation methods for targeted radionuclide therapy dosimetry. J Nucl Med. 2005;46:26P–26P
  71. He B, Frey EC, Tsui BM. Comparison and validation of conjugate view planar, model-based quantitative planar, and quantitative SPECT methods for whole organ activity estimation. J Nucl Med. 2005;46:50P–50P
  72. Dewaraja YK, Wilderman SJ, Ljungberg M, et al. Accurate dosimetry in I-131 radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840–849
  73. O'Donoghue JA, Sgouros G, Divgi CR, et al. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med. 2000;41:538–547
  74. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337–1341
  75. Roberson PL, Heidorn DB, Kessler ML, et al. Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. Cancer. 1994;73(3 suppl):912–918
  76. Muthuswamy MS, Roberson PL, Ten Haken RK, et al. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. Int J Radiat Oncol Biol Phys. 1996;35:165–172
  77. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res. 2003;159:182–189
  78. Howell RW, Rao DV, Sastry KS. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys. 1989;16:66–74
  79. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75–83
  80. Flynn AA, Pedley RB, Green AJ, et al. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother Radiopharm. 2001;16:391–400
  81. Flynn AA, Pedley RB, Green AJ, et al. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. Int J Radiat Biol. 2002;78:407–415
  82. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol. 1972;45:81–97
  83. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981–1997
  84. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–694
  85. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides. J Nucl Med. 1993;34:1801–1810
  86. Howell RW, Goddu SM, Rao DV. Application of the linear-quadratic model to radioimmunotherapy: Further support for the advantage of longer-lived radionuclides. J Nucl Med. 1994;35:1861–1869
  87. Mayer R, Dillehay LE, Shao Y, et al. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1995;32:147–157
  88. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000;46:947–958
  89. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94(4 suppl):1332–1348
  90. Flynn AA, Pedley RB, Green AJ, et al. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear–quadratic formulation. Int J Radiat Biol. 2001;77:507–517
  91. Shen S, Duan J, Meredith RF, et al. Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer. 2002;94(4 suppl):1264–1269
  92. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998;77:787–795
  93. Bodey RK, Evans PM, Flux GD. Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:228–241
  94. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89–97
  95. Zhu H, Jain RK, Baxter LT. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med. 1998;39:65–76
  96. Atwell JL, Breheney KA, Lawrence LJ, et al. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng. 1999;12:597–604
  97. Lawrence LJ, Kortt AA, Iliades P, et al. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett. 1998;425:479–484
  98. Le Gall F, Kipriyanov SM, Moldenhauer G, et al. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding. FEBS Lett. 1999;453:164–168
  99. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med. 2002;32:133–140
  100. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin- analogues. Q J Nucl Med. 1999;43:356–366
  101. McEwan AJ. Palliative therapy with bone seeking radiopharmaceuticals. Cancer Biother Radiopharm. 1998;13:413–426
  102. Giralt S, Bensinger W, Goodman M, et al. Ho-166-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003;102:2684–2691
  103. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451–1458
  104. Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet. 2001;358:1102–1103
  105. Otte A, Weiner SM, Cybulla M. Is radiation nephropathy caused by yttrium-90?. Lancet. 2002;359:979
  106. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447–1449
  107. Breitz H, Wendt R, Stabin M, et al. Dosimetry of high dose skeletal targeted radiotherapy (STR) with (166)Ho-DOTMP. Cancer Biother Radiopharm. 2003;18:225–230
  108. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys. 1996;23:1523–1529
  109. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47–51
  110. Zaider M, Hanin L. Biologically-equivalent dose and long-term survival time in radiation treatments. Phys Med Biol. Oct 2007;52:6355–6362
  111. Lucas JN, Tenjin T, Straume T, et al. Rapid human chromosome aberration analysis using fluorescence in situ hybridization. Int J Radiat Biol. 1989;56:35–44
  112. Millar WT. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol. 1991;64:242–251
  113. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations, Revised Edition. New York: The Society of Nuclear Medicine, Inc; 1991;
  114. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985–1994
  115. Frey EC, Gilland KL, Tsui BM. Application of task-based measures of image quality to optimization and evaluation of three-dimensional reconstruction-based compensation methods in myocardial perfusion SPECT. IEEE Trans Med Imaging. 2002;21:1040–1050

PII: S0001-2998(08)00075-5

doi: 10.1053/j.semnuclmed.2008.05.008

Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 321-334 , September 2008

Article Tools

* Image Usage & Resolution